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ValidationWe report the results of administration of the Portuguese–Brazilian translation of the Liverpool Adverse
Events Proﬁle (LAEP) to 100 patients (mean age=34.5, SD=12.12; 56 females), 61 with symptomatic partial
epilepsy (SPE) and 39 with idiopathic generalized epilepsy (IGE) (ILAE, 1989) who were on a stable anti-
epileptic drug (AED) regimen and being treated in a Brazilian tertiary epilepsy center. Carbamazepine was the
most commonly used AED (43.0%), followed by valproic acid (32.0%). Two or more AEDs were used by 69.0%
of patients. The mean LAEP score (19 questions) was 37.6 (SD=13.35). The most common adverse effects
were sleepiness (35.0%), memory problems (35.0%), and difﬁculty in concentrating (25.0%). Higher LAEP
scores were associated with polytherapy with three or more AEDs (P=0.005), female gender (Pb0.001),
older age (Pb0.001), and uncontrolled seizures (P=0.045). The intraclass coefﬁcient (test–retest reliability)
for LAEP overall score was 0.848 (95% CI=0.782–0.895), with a range from 0.370 (unsteadiness) to 0.750
(memory problems). Cronbach's α coefﬁcient (internal consistency) was 0.903. The LAEP was highly
correlated with Quality of Life in Epilepsy-31 inventory (r=−0.804, PN0.001) and Hospital Anxiety and
Depression Scale (Depression: r=0.637, Pb0.001; Anxiety: r=0.621, Pb0.001) dimensions. LAEP overall
scores were similar in people with SPE and IGE and were not helpful in differentiating adverse effects in these
two groups. Clinical variables that inﬂuenced global LAEP were seizure frequency (P=0.050) and generalized
tonic–clonic seizures in the last month (P=0.031) in the IGE group, and polytherapy with three or more AEDs
(P=0.003 and P=0.003) in both IGE and SPE groups.Departamento de Neurologia,
il. Fax: +55 11 5081 5005.
.
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The use of antiepileptic drugs (AEDs) is frequently associated with
adverse effects (AEs) such as idiosyncratic reactions, dose-related
neurocognitive effects, and complications of long-term use. Data
obtained from cross-sectional studies and randomized controlled
trials indicate that up to 80% of people with epilepsy taking AEDs
experience an AE [1–3].
The detection and minimization of AEs associated with treatment
are very important aspects of epilepsy care [1]. Previous studies have
suggested that direct questioning yields higher rates of AEs in patients
taking AEDs compared with spontaneous reports [4]. Clinical
experience suggests that AEs may be more disabling to the patient
than the seizures themselves [5], and this fact contributes to initial
treatment failure in up to 40% of the cases, reducing patient com-
pliance [6]. Evidence indicates that AEs negatively impact quality oflife (QOL), particularly cognitive and neurological impairment [1].
Interest in the effects of epilepsy on health-related QOL has led to
the development of epilepsy-speciﬁc QOL instruments, which may
be helpful in discriminating between patients treated with different
AEDs [7].
The Liverpool Adverse Events Proﬁle (LAEP) was developed in the
1990s by the Liverpool group to evaluate the most common negative
AEs reported by patients taking AEDs [8–10]. It is used to quantify
patients’ perceptions of AEs. The ability of the LAEP to detect and
quantify the presence and severity of AEs associated with different
AEDs was demonstrated in a large European study that included more
than 5000 patients [11]. The LAEP is a relatively simple instrument
with strong psychometric properties and can be used for investiga-
tional purposes, as well as in daily clinical practice [12]. The LAEP has
been validated in Spanish [13] and Chinese [14], but has not yet been
validated in Portuguese.
The availability of a questionnaire in different languages is par-
ticularly useful for multicenter studies, which require instruments
that have been translated and validated with respect to the cultural
particulars of the country where they will be used [15]. Comparison of
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symptomatic and idiopathic forms is important to better characterize
the treatment inﬂuence on prognosis of such distinct entities. In
this study we report the translation and validation of the LAEP in
a Portuguese–Brazilian version and the evaluation of its reliability,
validity, and ability to differentiate AEs of AEDs in symptomatic partial
(SPE) and idiopathic generalized (IGE) epilepsy.
2. Methods
2.1. Translation of the Liverpool Adverse Events Proﬁle
After permissionwas obtained from the Liverpool group (G. Baker)
to translate the original version of the LAEP in April 2010, the process
of adaptation to the Portuguese–Brazilian language was initiated and
included the following phases: (1) translation into Portuguese by a
qualiﬁed bilingual translator; (2) backtranslation into English by two
independent translators native in the target language; (3) assessment
of item comprehension by a multidisciplinary committee review; and
(4) pretest of the ﬁnal version to check for equivalencewith the source
version following international patterns [16].
This version was administered to a group of consecutive out-
patients in the Epilepsy Section of Hospital São Paulo, a tertiary care
center of the Universidade Federal de São Paulo, Brazil, with the aim
of testing and assessing the adequacy and comprehension of the
language used in the translated version. Patients older than 18 with
a conﬁrmed diagnosis of epilepsy were included in the study if they
were taking AEDs at a stable dose for at least 1 month and if they were
able to understand and answer the questions by themselves. Patients
with concomitant degenerative or chronic diseases and those with
symptomatic epilepsy caused by progressive diseases were excluded.
The subjects were recruited after ethics committee approval and gave
their written informed consent for the study.
The pretest with the ﬁnal version was administered to 30 out-
patients with epilepsy [17]. For each question, pertinence and com-
prehensibility were checked.
2.2. Instrument evaluation
The LAEP [4,10,18] is a self-administered, epilepsy-speciﬁc, 19-
item questionnaire using a scale of 1 to 4, with 4 indicating the most
frequent occurrences. Scores ranging from 19 to 76 may be calculated
to measure the total AE burden of a medication regimen [4]. The main
psychometric properties are considered appropriate if the internal
consistency of 0.95 and test–retest reliability of 0.85 are matched
[10]. To facilitate the analysis we transformed the range scale 1–4 into
0–100.
2.3. Measures used to assess construct validity
The Hospital Anxiety and Depression Scale (HADS) is a self-report
measure of anxiety and depression symptoms developed for use
in a hospital outpatient setting [19]. It consists of 14 items rated on
a 4-point scale with variable labels. Two subscales of seven items
separately measure anxiety and depression symptoms. Total subscale
scores range from 0 to 21, with higher scores representing higher
levels of anxiety or depression. The scale developers advise that scores
of 11 to 21 indicate a possible clinical diagnosis of anxiety or de-
pression, scores of 8 to 10 are considered borderline, and scores from
0 to 7 are considered to indicate noncases [20]. In this study we used
the validated Portuguese–Brazilian version of the HADS [21].
Quality of life was measured with the Portuguese–Brazilian version
of the disease-speciﬁc questionnaire Quality of Life in Epilepsy-31
(QOLIE-31) [22]. It includes 30 items organized into seven subscales—
Seizure Worry (5 items), Emotional Well-Being (5 items), Energy/
Fatigue (4 items), Social Functioning (5 items), Cognitive Functioning (6items), Medication Effects (3 items), Overall Quality of Life (2 items)—
and an additional item assessing overall health status. The raw scores
are rescaled from0 to 100,with higher values reﬂecting better QOL [23].
2.4. Data collection
The questionnaire was administered in a face-to-face interview to
100 patients to check the comprehensibility of the measures. The
subjects were separated into two groups according to their epilepsy:
group 1 comprised patients diagnosed with SPE, and group 2, patients
with IGE, based on International League Against Epilepsy classiﬁcation
[24].
Epileptologists documented demographic data, medical history,
and clinical characteristics. A pharmacist (H.H.M.) asked the subjects
to complete the LAEP, QOLIE-31, and HADS.
2.5. Evaluation of psychometric properties
2.5.1. Reliability
Assessment of reliability involved two steps. First, internal con-
sistency reliability was assessed with Cronbach's α coefﬁcient; the
correlation between each item and the global LAEP questionnaire was
calculated. Values N0.700 are conventionally considered acceptable
[25]. Second, test–retest reliability was determinedwith the intraclass
correlation coefﬁcient (ICC) between the LAEP completed at the initial
visit and that completed 2–3 weeks later by the same subject; values
N0.600 were considered statistically signiﬁcant. The medication type
and dose were the same as in the initial visit, to maintain the stability
of the clinical characteristics that may inﬂuence reproducibility.
2.5.2. Validity
Construct validity hypotheses were assessed as the relationships
between LAEP score ranges and speciﬁc instruments (QOLIE-31 do-
mains and HADS general score) or other external measures (e.g.,
demographic and clinical variables). We expected to show signiﬁcant
correlations between scales with similar or interdependent content.
The LAEP was expected to be sensitive to sociodemographic and
clinical characteristics. Pearson's correlation was used to analyze the
association of LAEP with QOLIE-31 and HADS.
Assessment of demographic and clinical characteristics consisted of
analysis of SPE and IGE groups separately. Variables such as educational
level, employment status, epilepsy group, seizure frequency, duration
of epilepsy, and treatment were chosen to evaluate construct validity
under the hypothesis that they were signiﬁcantly related to LAEP items.
Seizure frequency for SPE was divided into: controlled seizures, 1 or 2, 3
or 4, and ≥5 partial seizures per month. The criteria for classiﬁcation of
seizure control in the IGE group were as follows: controlled seizures;
generalized tonic–clonic seizures (GTCS), good (1/year), moderate
(1–4/year), or poor (4/year); myoclonic, good (5 single seizures or
clusters/month, rare or occasional seizures), moderate (6–14 single
seizures or clusters/month, several or frequent seizures) or poor (15
single seizures or clusters/month or daily seizures); and absence,
good (5/month, rare or occasional seizures), moderate (6–14/month,
several or frequent seizures), or poor (15/month, frequent or daily
seizures) [26]. The hypothesis was that higher seizure frequency
corresponded to worse QOL and higher LAEP scores.
A cutoff point of 45 on the LAEP was considered “toxicity,” as
suggested in previous studies [4], to compare the eventual differences
in QOL and clinical characteristics reported in the two groups. To
analyze the relationship between medication and AE frequency
we divided the daily AED doses into the following ranges (lower
and higher): carbamazepine (CBZ) ≤800 mg or N800 mg, valproic acid
(VPA) b1000 mg or ≥1000 mg, phenobarbital (PB) ≤100 mg or
N100 mg, clobazam (CLB) ≤10 mg or N10 mg, lamotrigine (LTG)
≤100 mg or N100 mg, and topiramate (TPM) ≤100 mg or N100 mg.
Analysis of variance, Student´s t test for independent samples, Fisher´s
Table 1
Etiology, localization, and syndromic classiﬁcation of the epilepsy groups.
Epilepsy group n
1. Symptomatic partial epilepsy 61
Mesial temporal sclerosis 47 (77.0%)
Neocortical (frontal 4, temporal 1,
frontotemporal 1, parietal 4)
10 (16.4%)
Mesial temporal sclerosis+neocortical
(frontal 2, occipital 1, multiple 1)
4 (6.6%)
2. Idiopathic generalized epilepsy 39
Juvenile myoclonic epilepsy 29 (74.3%)
Juvenile absence epilepsy 9 (23.1%)
Nonclassiﬁed 1 (2.6%)
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0.050 were considered statistically signiﬁcant [27].
3. Results
3.1. Cultural adaptation
The ﬁnal Portuguese–Brazilian version of the LAEP was completed
by 100 subjects. The translation was adapted and complementary
information was needed for some items to clarify their meaning. For
example, the item “Unsteadiness” was amended to read “Unsteadi-Table 2
Sociodemographic and clinical characteristics of 100 patients.
Characteristic Epilepsy type
SPE (n=61) IGE (n=39)
Gender
Male 44.3% (27) 43.6% (17)
Female 55.7% (34) 56.4% (22)
Age
Mean (SD) 37.5 (11.52) 29.7 (11.60)
16–34.5 44.3% (27) 74.4% (29
34.5–70 55.7% (34) 25.6%(10)
Marital status
Single 50.8% (31) 71.8% (28)
Married 41.0% (25) 23.1% (9)
Other 8.2% (5) 5.1% (2)
Educational level
Elementary school 29.5% (18) 15.4% (6)
High school 52.5% (32) 69.2% (27)
University 18.0% (11) 15.4% (6)
Employment status
Employed 44.3% (27) 59.0% (23)
Unemployed 24.6% (15) 7.7% (3)
Students/housewives/never worked 3.3% (2) 25.6% (10)
Retired or with ill-health beneﬁts 27.9% (17) 7.7% (3)
Epilepsy duration, mean (SD) 20.9 (11.76) 18.4 (13.15)
Seizure frequency
Seizure free 39.3% (24) 35.9% (14)
Uncontrolled seizures 60.7% (37) 64.1% (25)
Treatment duration, mean (SD) 19.3 (11.14) 17.5 (13.53)
AED
Carbamazepine 63.9% (39) 10.3% (4)
Valproic acid 4.9% (3) 74.4 % (29)
Phenobarbital 29.5% (18) 23.1% (9)
Lamotrigine 13.1% (8) 23.1 % (9)
Topiramate 11.5 % (7) 20.5% (8)
Phenytoin 16.4% (9) 0.0% (0)
Clobazam 42.6% (26) 2.6% (1)
Othera 27.9% (17) 20.5% (8)
Number of AEDs
1 12.9% (11) 46.2% (18)
2 45.2% (34) 35.9% (14)
≥3 26.2% (16) 18.0% (7)
Note. Statistically signiﬁcant values are in boldface. P values determined with Student's t test
a Ethosuximide, clonazepam, diazepam, oxcarbazepine.ness of the Body.” The item “Restlessness”was changed to “Agitation.”
The item “Feelings of Aggression” required modiﬁcation in the
sequence of the questionnaire, because this term represents more
than “Nervousness,” and it was replaced after this item, to clarify
its meaning. Details are provided in the Supplementary Material
(see Appendix).
3.2. Demographic and clinical characteristics
The mean age of the 100 patients was 34.5 years (SD=12.12); 61
(61.0%) subjects had SPE and 39 (39.0%) IGE (Table 1). As half of the
patients had difﬁcult-to-treat epilepsies such as mesial temporal
sclerosis and long-duration juvenile myoclonic epilepsy (JME), two
or more AEDs were used by 69 (69.0%) patients. CBZ was the most
common treatment and was used by 43.0% of the sample, followed by
VPA (32.0%), PB (27.0%), CLB (27.0%), LTG (17.0%), and TPM (15.0%).
The sociodemographic and clinical characteristics of the two epilep-
sies are detailed in Table 2.
Twenty-ﬁve patients (64.1%) from the IGE group had experienced
seizures in the month preceding the study; 8 (20.5%) had good, 4
(10.4%) moderate, and 13 (33.3%) poor control of their seizures. As for
seizure type, 16 (41.0%) had absences, 12 (30.8%) myoclonic seizures,
and 11 (28.2%) GTCS in the preceding month. Thirty-seven patients
(60.7%) in the SPE group had had complex partial seizures in themonth
preceding the study at the followingmonthly seizure frequencies: 1 or 2
in 10 (16.4%), 3 or 4 in 20 (32.8%), and N5 in 7 (11.5%).P value LAEP overall score P value
b45 (n=69) ≥45 (n=31)
1.000 56.5% (39) 16.1% (5) b0.001
43.5% (30) 83.9% (26)
0.001 32.9 (12.59) 38.0 (10.36) 0.050
0.004 65.2% (45) 35.5% (11) b0.001
34.8% (24) 64.5% (20)
0.124 62.3% (43) 51.6% (16) 0.261
29.0% (20) 45.2% (14)
8.6% (6) 3.2% (1)
0.208 21.8%(15) 29.0%(9) 0.596
62.3% (43) 51.6% (16)
15.9% (11) 19.4% (6)
b0.001 56.6%(39) 35.5%(11) 0.217
15.9% (11) 22.6% (7)
11.6% (8) 12.9% (4)
15.9% (11) 29.0% (9)
0.325 19.4 (12.21) 21.2 (12.65) 0.516
0.834 44.9% (31) 22.6% (7) 0.045
55.1% (38) 77.4% (24)
0.475 18.0 (11.85) 19.9 (12.72) 0.473
b0.001 37.7% (26) 54.8% (17) 0.129
b0.001 33.3% (23) 29.0% (9) 0.817
0.645 24.6% (17) 32.3% (10) 0.470
0.275 13.0% (9) 25.8% (8) 0.151
0.257 10.1% (7) 25.8% (8) 0.067
0.006 13.0% (9) 3.2% (1) 0.167
b0.001 26.1% (18) 29.0% (9) 0.810
0.482 21.7% (15) 32.3% (10) 0.320
0.012 36.2% (25) 12.9% (4) 0.005
49.3% (34) 45.2% (14)
14.4%(10) 41.9%(13)
or Fisher's test. IGE, idiopathic generalized epilepsy; SPE, symptomatic partial epilepsy.
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and the most common AEs reported as occurring “frequently” were
Somnolence (35.0%), Memory Problems (35.0%), and Difﬁculty in
Concentrating (25.0%). Comparison between LAEP scores b45 or ≥45
and QOLIE-31 domain scores showed association of more AEs with
worse QOLIE-31 and HADS (Pb0.001) scores.
Correlations of LAEP scores with sociodemographic characteristics
were studied using a cutoff point of 45 (b45 and ≥45) (Table 2). The
questionnaire correlatedwell with the number of AEDs taken. Patients
who used polytherapy (two or more drugs) experienced more AEs
than those in monotherapy (P=0.018). In the group of patients with
LAEP scores N45 there were more women (26: 17 with SPE and 13 of
these receiving CBZ) than men (5: 4 with SPE using CBZ) (Pb0.001).
As compared with younger age (16–34.5 years), older age (34.5–
70 years) was associated with the presence of AEs (Pb0.001). Higher
seizure frequency was associated with LAEP scores ≥45 (P=0.045).
Level of education, employment status, duration of epilepsy, and
epilepsy group did not affect LAEP results.
3.3. Internal consistency and reliability
Internal consistency of the overall score as measured with
Cronbach's α coefﬁcient was 0.903 (95% CI: 0.872–0.928). Test–retest
reliability of the Portuguese–Brazilian version of the LAEP as
determined with the ICC was 0.848 (95% CI: 0.782–0.895), ranging
from 0.370 (Unsteadiness) to 0.750 (Memory Problems), as demon-
strated in Table 3.
3.4. Construct validity
A strong negative correlation of LAEP Overall score with QOLIE-31
wasobserved (r=−0.804,Pb0.001), ranging from r=−0.491,Pb0.001Table 3
Reliability, score distribution, and LAEP item mean scores at visit 1 for 100 patients.
Reliability
Internal consistency, Cronbach´s α 0.903
Mean (SD) [95% CI] (scale 19-76)
Visit 1 37.6 (13.35) [34.9–40.2]
Visit 2 35.9 (13.29) [33.2–38.5]






LAEP item, visit 1, meana (SD) [ICC]
Unsteadiness 19.3 (31.13) [0.370]b
Tiredness 37.0 (40.17) [0.668]
Restlessness 36.7 (40.06) [0.668]
Nervousness and/or Agitation 43.3 (38.92) [0.560]
Feelings of Aggression 19.7 (33.87) [0.649]
Headache 38.7 (39.56) [0.586]
Hair Loss 29.0 (42.55) [0.621]
Problems with Skin, e.g., acne, rash 23.0 (38.10) [0.608]
Double or Blurred Vision 27.3 (37.72) [0.562]
Upset Stomach 33.7 (42.51) [0.717]
Difﬁculty in Concentrating 44.7 (40.82) [0.718]
Trouble with Mouth and Gums 13.3 (31.43) [0.495]b
Shaky Hands 38.3 (39.46) [0.651]
Weight Gain 16.3 (34.33) [0.394]b
Dizziness 33.7 (38.34) [0.737]
Sleepiness 55.0 (41.94) [0.718]
Depression 31.7 (39.46) [0.695]
Memory Problems 50.7 (43.80) [0.750]
Disturbed Sleep 27.3 (41.13) [0.509]b
Overall 37.6 (13.35) [0.783]
a Scores converted to a scale of 0 to 100.
b Indicates low reliability.for the QOLIE-31 scale Overall Quality of Life to r=−0.752, Pb0.001
for Cognitive Function. There was a strong positive correlation between
LAEP scores and the two HADS dimensions Depression (r=0.637,
Pb0.001) and Anxiety (r=0.621, Pb0.001) (Figs. 1 and 2).
3.5. Comparison between epilepsy types
Patients with SPE obtained higher mean (SD) scores on the LAEP
items Sleepiness, 60.1 (41.19), and Memory Problems, 56.3 (43.69);
63.9% (39) of the patients in this group were taking CBZ (mean daily
dose=1062 mg, SD=358.8). In the IGE group higher scores on the
LAEP items Sleepiness, 47.0 (42.38), and Memory Problems, 41.9
(43.07) were also observed; 74.4% (29) of these patients were taking
VPA (mean daily dose=964 mg, SD=434) (Fig. 3).
Uncontrolled seizures inﬂuenced the increase in LAEP scores in
both groups, especially in patients with IGE and poor seizure control
(P=0.015); in SPE there was a tendency in the subgroup with 3 or 4
seizures/month (P=0.07).
Liverpool Adverse Event Proﬁle total scores were similar for the two
groupsandnostatistical signiﬁcancewas demonstrated (Fig. 3). Analysis
of variance (ANOVA) revealed the clinical variables that inﬂuenced
global LAEP: seizure frequency (P=0.050) and GTCS (P=0.031) in the
IGE group, andpolytherapywith three ormore AEDs (P=0.003) in both
the IGE and SPE groups. The IGE group scored higher on the QOLIE-31
(mean=69.2, SD=18.38) and lower on the HADS Depression dimen-
sion (20.8, SD=16.76) when compared with patients in the SPE group
(59.6, SD=19.44, P=0.016, and 28.0, SD=18.32, P=0.048, respec-
tively). The IGE group scored higher (P=0.022) on the QOLIE-31 scale
Medication Effects (65.5, SD=31.33) than those with SPE (50.8,
SD=30.61).
3.6. Antiepileptic drug ﬁndings
Twenty-seven of 43 patients taking higher doses of CBZ (N800 mg/
day) scored lower on the Nervousness and/or Agitation (P=0.006),
Hair Loss (P=0.045), Difﬁculty in Concentrating (P=0.003), Problems
withMouth andGums (P=0.001), andDepression (P=0.042) items of
the LAEP, as well as Overall score (P=0.025).Fig. 1. Correlation of Liverpool Adverse Events Proﬁle scores with Hospital Anxiety and
Depression Scale (HADS) and Quality of Life in Epilepsy-31 inventory (QOLIE-31)
scores.
Fig. 2. Comparison of LAEP scores b45 or ≥45 with HADS and QOLIE-31 domain scores.
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had higher scores on the items Unsteadiness (P=0.005) and Feelings
of Aggression (P=0.037). The only item that differed with respect to
dose in 10 of 27 subjects taking PB (≤100 and N100 mg/day) was
Weight Gain (P=0.038). Ten of 27 subjects taking CLB differed on the
items Tiredness (P=0.048) and Headache (P=0.044) in different doseLegend. SPE: symptomatic partial epilepsy; IGE: idiopathic generalized e
Fig. 3. Comparison of the LAEP scores of the symptomatic parranges (≤10 and N10 mg/day). There were no differences with respect
to dose in those taking LTG and TPM. Range ﬁndings for the main AEDs
are summarized in Table 4.
4. Discussion
The Brazilian–Portuguese version of the LAEP was culturally
validated in a sample of 100 outpatients with two different types of
epilepsy (SPE/IGE), and the total score was found to be similar to
those previously reported [13,14]. In this study 69% of patients had
scores b45 in the ﬁrst interview, demonstrating the low toxicity of
AEDs in the majority of the sample.
4.1. Psychometric properties of the Liverpool Adverse Events Proﬁle
This version of the LAEP demonstrated satisfactory psychometric
properties. Internal consistency (Cronbach`s α=0.90) was good
on all items. This ﬁnding is similar to that reported for the original
scale [10] as well as the Spanish [13] and Chinese [14] versions, as
summarized in Table 5.
Test–retest reliability was satisfactory (ICC=0.78), which sup-
ports the temporal stability of the instrument. The lower ICCs for the
items Unsteadiness, Problems with Mouth and Gums, and Weight
Gain can be explained by the lack of a physical examination, which
may have led to underrepresentation of certain AEs, such as
nystagmus, gait disturbances, tremor, hair loss, and weight changes
[28]. This discrepancy was also observed in a large multicenter study
of 509 patients in which at least 36% of AEs were not self-reported
despite being found on physical and neurological examination [29].
Most of the construct validity hypotheses were reached, and all
QOLIE-31 domains were strongly correlated with the LAEP items. In
this group higher LAEP scores were correlated with lower QOLIE-31
scores, which conﬁrms the negative impact of AEs on QOL [4].pilepsy.
tial epilepsy and idiopathic generalized epilepsy groups.
Table 4
Antiepileptic drug ranges and signiﬁcant differences in LAEP items between drugs a.
Carbamazepine Valproic acid Phenobarbital Clobazam
Number of patients 43 32 27 27
Dose range ≤800 mg/N800 mg b1000 mg/≥1000 mg ≤100 mg/N100 mg ≤10 mg/N10 mg
Number of patients per group 16/27 15/17 17/10 17/10
LAEP item
Unsteadiness 31.3/14.8 (0.192)a 2.2/31.4 (0.005)b 33.3/13.3 (0.080) 23.5/20.0 (0.575)
Tiredness 54.2/33.3 (0.097) 22.2/39.2 (0.357) 47.1/30.0 (0.402) 45.1/13.3 (0.048)b
Nervousness and/or Agitation 77.1/46.9 (0.006)b 35.6/33.3 (0.934) 62.7/40.0 (0.145) 52.9/63.3 (0.398)
Feelings of Aggression 20.8/25.9 (0.805) 6.7/27.5 (0.037)b 25.5/23.3 (0.705) 25.5/26.7 (0.884)
Headache 39.6/44.4 (0.661) 33.3/33.3 (0.853) 52.9/43.3 (0.533) 51.0/20.0 (0.044)b
Hair loss 35.4/12.3 (0.045)b 31.1/51.0 (0.264) 33.3/20.0 (0.366) 29.4/23.3 (0.787)
Difﬁculty in Concentrating 79.2/39.5 (0.003)b 26.7/37.3 (0.432) 64.7/30.0 (0.059) 58.8/53.3 (0.731)
Trouble with Mouth and Gums 35.4/3.7 (0.001)b 15.6/5.9 (0.135) 3.9/10.0 (0.963) 21.6/10.0 (0.414)
Weight Gain 12.5/17.3 (0.737) 15.6/31.4 (0.282) 27.5/0.0 (0.038)b 7.8/10.0 (0.927)
Depression 50.0/24.7 (0.042)b 22.2/29.4 (0.754) 37.3/10.0 (0.076) 41.2/36.7 (0.763)
Overall score 47.6/32.2 (0.025)b 21.8/33.6 (0.226) 41.5/24.9 (0.063) 42.0/31.6 (0.258)
a LAEP scores converted to scale of 0 to 100. Mean at low dose/high dose (P value, Mann–Whitney's test).
b In boldface are values for which Pb0.050.
516 H.H. Martins et al. / Epilepsy & Behavior 22 (2011) 511–517Hospital Anxiety and Depression Scale scores also were strongly
correlated with LAEP scores. Many of the symptoms listed on the LAEP
as possible effects of AEDs are also symptoms of anxiety and depression.
Comorbid psychiatric symptoms are well known to occur in patients
with epilepsy. These results agree with the previously reported
association between AEs of antiepileptic medication and mood
[12,30]. In the present study 44% of patients reported depression on
the LAEP, and on the related anxiety symptoms, 53% reported
Restlessness and 63% Nervousness/Agitation. It has been reported that
depression symptoms may be secondary to the use of AEDs [31] and
may be a strong predictor of QOL in epilepsy [32].
4.2. Sociodemographic and clinical analysis of the Liverpool Adverse
Events Proﬁle
There was a strong and consistent association of gender, age,
seizure frequency, andpolytherapywith LAEP scores. Thereweremore
women in the group with higher toxicity. Although previous studies
have attributed this association to the endocrine effects of AEDs,
especially VPA, in women, such as weight gain, skin problems, and
teratogenicity [33], most of the women in our study with LAEP scores
indicating toxicity had SPE and were taking CBZ. LAEP scores were
found to be inﬂuenced by age, especially in the range 34.5–70 years,
reﬂecting an increase in AEswith time. This conﬁrms previousﬁndings
that the rates of AEs can be inﬂuenced by age, gender, comorbidity,
duration of treatment, personality traits, and mood state, including
anxiety and depression [34].
Seizure frequency and seizure type were strongly related to LAEP
scores. Higher seizure frequency was associated with higher LAEP
scores. This ﬁnding was not in accordance with other studies that
found no relationship between seizure frequency and the LAEP or
other measures of AEs [13,35]. There has been some controversy
regarding the role of QOL, AEs, and seizure frequency. Some authors
consider QOL more important than the AEs themselves, but other
groups believe that the AEs of AEDs may be more disabling to the
patient than the seizures [5,18,36]. Our ﬁndings may have also been
inﬂuenced by the subjective character of the LAEP and the possibilityTable 5
Comparison of mean score, Cronbach´sα, and test–retest reliability in different versions
of the LAEP.
Version Mean (SD) Cronbach´s α Test–retest reliability
Portuguese–Brazilian 37.6 (13.3) 0.90 0.78
Spanish 36.4 (9.7) 0.84 0.81
Chinese 30.7 (11.0) 0.90 0.80that patients with higher seizure frequency paid more attention
to AEs.
With respect to epilepsy groups, the only association found was the
presence of GTCS in the preceding month in patients with IGE and
higher LAEP scores. Thismay reﬂect the fact that themajority of patients
diagnosed with JME were in this group and that polytherapy is used in
these cases. Although an impact on QOL has been demonstrated for
patientswith JME [22,37] andwas conﬁrmed in the present study, other
factors such as the pathophysiological implications of frequent
uncontrolled GTCS may lead to worse prognosis and higher burden
for these patients.
Overall, the LAEP results for patients with two distinct entities
such as difﬁcult-to-treat SPE and IGE did not differ. This fact is not
explained by sociodemographic data or types and number of AEDs
which differed between the groups. Measurements of QOL in this and
other studies were reported to be worse in patients with SPE than in
those with IGE [22,37]. HADS Depression scores also differed between
the two groups. Nevertheless, in our study the LAEP was strongly
correlated with QOLIE-31 and HADS. We hypothesize that although
the LAEP is appropriate for diverse epilepsies, it does not differentiate
the overall burden of AEs in SPE and IGE, not only because of the
subjective nature of QOL, but also because of the speciﬁc AEs of drugs
indicated for a particular epilepsy seizure type. The LAEP has been
described as an instrument for quantiﬁcation of patients' perceptions
of the AEs of AEDs [10], and to our knowledge, this is the ﬁrst study to
evaluate the relationship of different epilepsies to the LAEP. Other
instruments that take into account seizure types and frequency as
well as systemic, neurological, and behavioral modiﬁcations after the
initiation of a speciﬁc AED are necessary [38].
4.3. Type of antiepileptic drug treatment and Liverpool Adverse Events
Proﬁle
The most commonly reported AEs in the sample of patients were
Sleepiness, Difﬁculty in Concentrating, and Memory Problems. These
can be associated with the most frequently used AEDs, CBZ and VPA,
which may cause these common AEs. Similar results were obtained in
a large European study with more than 5000 patients that showed
that the most common AEs of CBZ and VPA are tiredness, memory
problems, difﬁculty in concentration, and sleepiness [1].
Polytherapy was associated with higher LAEP scores in the IGE and
SPE groups. In recent decades, the availability of new compounds with
potentially fewer AEs and drug interactions has led to the use of high
doses of AEDs in polytherapy with the goal of better seizure control.
This strategy, in turn, may have impaired QOL and resulted in more
AEs [39].
517H.H. Martins et al. / Epilepsy & Behavior 22 (2011) 511–517Higher LAEP scores were obtained by patients in different dose
range groups of CBZ (5 items), VPA and CLB (2 items each), and PB
(1 item). Some of these items are well known to have dose-related
neurocognitive AEs such as nervousness/agitation, difﬁculty in con-
centration, and depression for CBZ; unsteadiness and feelings of
aggression for VPA [40]; and tiredness and headache for CLB [41].
Nevertheless, these AEs were found to be associated with lower doses
of CBZ and CLB, which may be due to the difﬁculty patients have in
recognizing these problems among central nervous system-related
AEs of other AEDS at higher doses. The same was observed in 10
patients taking more than 100 mg of PB per day who did not report
weight gain on the LAEP although all 17 subjects in the low-dose
group (b100 mg) did. Surprisingly weight gain in a relatively young
population differed neither in distinct epilepsies nor in the two
subgroups of VPA and TPM doses.
We acknowledge some restrictions of this study such as the
tertiary care character of our institution, as well as the large number of
patients with drug-resistant seizures in the sample. Potential
limitations of the LAEP may be its subjectivity; the lack of a physical
examination to medically conﬁrm some AEs such as weight changes,
nystagmus, ataxia, coordination and speech abnormalities; and the
lack of objective measures of systemic involvement like hepatic and
hematological AEs. Other concerns with the LAEP are the possibility of
overreporting as a result of the direct approach of the questionnaire
[12] and the absence of a median point in its 4-point rating scale [42].
5. Conclusion
The Portuguese–Brazilian version of the LAEP was conﬁrmed to be
a reliable and valid instrument for assessing AEs in patients with
epilepsy with important limitations in physical symptoms. This study
demonstrated that LAEP items were associated with speciﬁc AEs of
drugs without a clear dose-dependent pattern. Although LAEP Overall
score was not helpful in differentiating epilepsies, this scale may be
useful for continued screening of patients in clinical trials of AEDs that
affect the items covered by this subjective questionnaire.
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